Risk of Infection in Patients with Lymphoma Receiving Rituximab: Systematic Review and Meta-analysis

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2011 Apr 13

PMID 21481281

Citations 46

Authors

Simone Lanini

Aoife C Molloy

Paul E Fine

Archibald G Prentice

Giuseppe Ippolito

Christopher C Kibbler

Affiliations

Soon will be listed here.

Abstract

Background: The addition of Rituximab (R) to standard chemotherapy (C) has been reported to improve the end of treatment outcome in patients affected by CD-20 positive malignant lymphomas (CD20+ ML). Nevertheless, given the profound and prolonged immunosuppression produced by R there are concerns that severe infections may arise. A systematic review and meta-analysis were performed to determine whether or not the addition of R to C may increase the risk of severe infections in adults undergoing induction therapy for CD20+ ML.

Methods: Only randomised controlled trials comparing R-C to C standard alone in adult patients with CD20+ ML were included. Meta-analysis was performed on overall incidence of severe infection, risk of dying as the consequence of infection, risk of febrile neutropenia, risk of severe leucopenia, risk of severe granulocytopenia and overall response assuming a fixed effect model. Heterogeneity was investigated, if present and I2 >20%, according to several predefined baseline characteristics of the study populations.

Results: Several relevant results have emerged. First, the addition of R to standard C does not increase the overall risk of severe infections (RR = 1.00; 95% CI 0.87 to 1.14) nor does it increase the risk of dying as a consequence of infection (RR = 1.60; 95% CI 0.68 to 3.75). Second, we confirmed that the addition of R to standard C increases the proportion of overall response (RR = 1.12; 95% CI 1.09 to 1.15), but it also increases the risk of severe leucopenia (RR = 1.24; 95% CI 1.12 to 1.37) and granulocytopenia (RR = 1.07; 95% CI 1.02 to 1.12).

Conclusions: R-C is superior to standard C in terms of overall response and it does not increase the overall incidence of severe infection. However, data on special groups of patients (for example, HIV positive subjects and HBV carriers) are lacking. In our opinion more studies are needed to explore the potential effect of R on silent and chronic viral infections.

Citing Articles

The long-term risk of immune-related conditions in survivors of diffuse large B-cell lymphoma: A Danish nationwide registry study.

Pedersen L, Klausen N, Jensen J, Bacevicius E, Brown P, Jorgensen J EJHaem. 2025; 6(1):e1070.

PMID: 39866948 PMC: 11756995. DOI: 10.1002/jha2.1070.

Hypogammaglobulinemia and Infection Events in Patients with Autoimmune Diseases Treated with Rituximab: 10 Years Real-Life Experience.

Nie Y, Zhang N, Li J, Wu D, Yang Y, Zhang L J Clin Immunol. 2024; 44(8):179.

PMID: 39150626 DOI: 10.1007/s10875-024-01773-y.

Effect of rituximab on immune status in children with aggressive mature B-cell lymphoma/leukemia-a prospective study from CCCG-BNHL-2015.

Dong J, Xu Z, Guo X, Ye F, Fan C, Gao J Heliyon. 2024; 10(5):e27305.

PMID: 38495131 PMC: 10943340. DOI: 10.1016/j.heliyon.2024.e27305.

Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial.

Alexander S, Auperin A, Bomken S, Csoka M, Kazanowska B, Chiang A Lancet Haematol. 2023; 10(6):e445-e457.

PMID: 37094596 PMC: 10350968. DOI: 10.1016/S2352-3026(23)00062-5.

Modeling and affinity maturation of an anti-CD20 nanobody: a comprehensive in-silico investigation.

Poustforoosh A, Faramarz S, Negahdaripour M, Hashemipour H Sci Rep. 2023; 13(1):582.

PMID: 36631511 PMC: 9834265. DOI: 10.1038/s41598-023-27926-4.

References

Mawhorter S, Sierk A, Staugaitis S, Avery R, Sobecks R, Prayson R . Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma. Clin Lymphoma Myeloma. 2005; 6(3):248-50. DOI: 10.3816/CLM.2005.n.053. View

Suzan F, Ammor M, Ribrag V . Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med. 2001; 345(13):1000. DOI: 10.1056/NEJM200109273451315. View

Cartron G, Zhao-Yang L, Baudard M, Kanouni T, Rouille V, Quittet P . Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol. 2008; 26(16):2725-31. PMC: 2443403. DOI: 10.1200/JCO.2007.13.7729. View

Salles G, Seymour J, Offner F, Lopez-Guillermo A, Belada D, Xerri L . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2010; 377(9759):42-51. DOI: 10.1016/S0140-6736(10)62175-7. View

Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M . Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev. 2007; (4):CD003805. PMC: 9017066. DOI: 10.1002/14651858.CD003805.pub2. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Aksoy S, Harputluoglu H, Kilickap S, Dede D, Dizdar O, Altundag K . Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007; 48(7):1307-12. DOI: 10.1080/10428190701411441. View

Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z . A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol. 2009; 49(1):3-12. DOI: 10.3109/02841860903150502. View

Archimbaud C, Bailly J, Chambon M, Tournilhac O, Travade P, Peigue-Lafeuille H . Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000. J Clin Microbiol. 2003; 41(10):4605-10. PMC: 254333. DOI: 10.1128/JCM.41.10.4605-4610.2003. View

10.

Spina M, Jaeger U, Sparano J, Talamini R, Simonelli C, Michieli M . Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2004; 105(5):1891-7. DOI: 10.1182/blood-2004-08-3300. View

11.

Hamaki T, Kami M, Kusumi E, Ueyama J, Miyakoshi S, Morinaga S . Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol. 2002; 68(4):292-4. DOI: 10.1002/ajh.10043. View

12.

Dervite I, Hober D, Morel P . Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001; 344(1):68-9. DOI: 10.1056/NEJM200101043440120. View

13.

Coiffier B . Treatment of non-Hodgkin's lymphoma: a look over the past decade. Clin Lymphoma Myeloma. 2006; 7 Suppl 1:S7-13. DOI: 10.3816/clm.2006.s.002. View

14.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

15.

Song K, Mollee P, Patterson B, Brien W, Crump M . Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol. 2002; 119(1):125-7. DOI: 10.1046/j.1365-2141.2002.03778.x. View

16.

Padate B, Keidan J . Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab. Clin Lab Haematol. 2006; 28(1):69-71. DOI: 10.1111/j.1365-2257.2006.00751.x. View

17.

Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4):1244. DOI: 10.1200/JCO.1999.17.4.1244. View

18.

Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz S . Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009; 101(4):248-55. DOI: 10.1093/jnci/djn478. View

19.

Precupanu C, Girodet J, Mariani P, Zanni M, Mathiot C, Escande M . Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation. Am J Hematol. 2009; 84(2):127-8. DOI: 10.1002/ajh.21309. View

20.

Targhetta C, Cabras M, Mamusa A, Mascia G, Angelucci E . Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica. 2008; 93(6):951-2. DOI: 10.3324/haematol.12557. View